2-BBB develops medicines for the treatment of brain and eye diseases
We believe that we can transform the lives of those affected faster and more successful by combining known disease targets and compounds with established drug delivery systems united with safe targeting technology. This has led to two programs in clinical development for the treatment of brain cancer and neuro-inflammatory diseases.
At the heart of 2-BBB’s CNS drug delivery platform lays the G-Technology®, a proprietary CNS targeted liposome formulation.
2-BBB started as a spin-off company from the Blood-Brain Barrier Research Group of the Leiden Academic Center for Drug Research (LACDR) from Leiden University in the Netherlands to develop medicines for the treatment of devastating brain diseases.